Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2018 - 2025)

Cyclerion Therapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $1.8 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $1.8 million; the TTM figure through Sep 2025 stood at $3.1 million (changed N/A YoY), while the FY2023 annual figure was $5.0 million, up 17224.14% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $1.8 million, up from -$130000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $30.6 million in Q2 2021, with the low at -$130000.0 in Q2 2025.
• The 3-year median for Cash from Financing Activities is $43000.0 (2021), against an average of $3.8 million.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities jumped 2600.0% in 2021, then sank 99.94% in 2022.
• Cyclerion Therapeutics' Cash from Financing Activities stood at $85000.0 in 2021, then slumped by 85.88% to $12000.0 in 2022, then surged by 15116.67% to $1.8 million in 2025.
• Business Quant data shows CYCN's Cash from Financing Activities at $1.8 million in Q3 2025, -$130000.0 in Q2 2025, and $1.4 million in Q1 2025.